Fair Value Calculator Fair Value Calculator
EN DE

PhytoHealth Corporation (4108) Fair Value & Analysis

Healthcare · TW · Market cap 2.4B TWD

PC PhytoHealth Corporation 4108 · TW
Price12.00 TWD
Fair Value3.95 TWD
Upside-67.1%
Quality39/100
Watch PhytoHealth Corporation for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range 2.60 TWD – 4.93 TWD

Fair value as of: Jul 11, 2026

From 1 valuation models · updated today

Fair value updated Jul 11, 2026 — revised from 42.43 TWD to 3.95 TWD (−90.7%) since Jun 24, 2026. Share price −3.2% over the past month.

Price vs Fair Value (12 months)

17.30 TWD 11.55 TWD Fair Value 3.95 TWD Jun 2025 Jul 2026

12‑month range 11.55 TWD – 17.30 TWD · fair‑value band 2.60 TWD – 4.93 TWD · the 12.00 TWD price screens above the 3.95 TWD fair value. As of Jul 11, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

PhytoHealth Corporation (4108) currently trades at 12.00 TWD, while our model-based Fair Value estimate is 3.95 TWD — implying the stock looks roughly 67.1% overvalued today. We read business quality at 39/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, PhytoHealth Corporation generated revenue of 139M TWD at a net margin of -42.7%. Revenue grew 13.0% year over year. It earns a return on equity of -4.8%. The balance sheet holds a net cash position of 71.1M TWD. Fundamentals as of Jul 11, 2026

Our scenario range runs from 2.60 TWD (bear case) to 4.93 TWD (bull case); at 12.00 TWD, the current price sits above that range. The share trades about 33% below its 52-week high and 5% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -23% fair-value upside — at -67%, 4108 screens richer than that median.

Key figures & financial health

Revenue (TTM) 139M TWD
Revenue growth (YoY) +13.0%
Net margin -42.7%
Return on equity -4.8%
Free cash flow −45.3M TWD FY2025
Operating margin -96.2%
More key figures
EPS (TTM) -0.2900 TWD
EPS growth (YoY) +50.0%
Net cash 71.1M TWD FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 11, 2026. TTM = trailing twelve months.

About the company

PhytoHealth Corporation researches, develops, manufactures, and sells medicines, cosmetics, Class B medicines, complementary foods, and other related products in Taiwan. It operates in three segments: Medicines and Health Food, Medical Diagnosis, and Precision Medical Equipment and Instruments. The Medicines and Health Food segment manufactures and sells Chinese medicine materials and new drugs. The Medical Diagnosis segment develops and sells smart medical imaging diagnostic products. The Precision Medical Equipment and Instruments segment engages in the research and development, manufacturing, and sale of ultrasound probes and analysis systems. Its products under development include PHN031, which has completed Phase II clinical trials for the treatment of osteoporosis, and PHN033, which has completed Phase II clinical trials for the treatment of diabetic nephropathy. The company is also developing PHN016, which is in Phase II clinical trials for the treatment of cancer, and …

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

PhytoHealth Corporation reported revenue of 135M TWD in FY2025 versus 169M TWD in FY2021, a compound −5.5%/yr. Reported net income was −58.2M TWD in FY2025.

Revenue −5.5%/yr
FY21 169M TWD
FY22 135M TWD
FY23 162M TWD
FY24 154M TWD
FY25 135M TWD
Net income
FY21 −78.0M TWD
FY22 −115M TWD
FY23 −47.1M TWD
FY24 −73.5M TWD
FY25 −58.2M TWD

Is 4108 fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "PhytoHealth Corporation Fair Value". https://www.fairvalue-calculator.com/stock/4108

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 11, 2026).

Stock Price Fair Value vs Fair Value
Jiangsu Hengrui Pharmaceuticals Co 1276 HK$57.85 HK$29.84 -48%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,786 ₹991.46 -44%
Zoetis Inc Z1TS34 R$25.93 R$19.70 -24%
Hansoh Pharmaceutical Group 3692 HK$29.32 HK$23.94 -18%
Divi's Laboratories Limited DIVISLAB ₹6,747 ₹2,035 -70%
Torrent Pharmaceuticals Limited TORNTPHARM ₹4,464 ₹1,504 -66%
Cipla Limited CIPLA ₹1,416 ₹1,466 +4%
Zydus Lifesciences Limited ZYDUSLIFE ₹1,089 ₹841.98 -23%
Dr. Reddy's Laboratories Limited DRREDDY ₹1,291 ₹1,053 -18%
Lupin Limited LUPIN ₹2,247 ₹2,697 +20%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is PhytoHealth Corporation (4108) undervalued?
As of Jul 11, 2026, our model estimates a fair value of 3.95 TWD versus a price of 12.00 TWD — about −67% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4108?
Our model-based fair value for PhytoHealth Corporation is 3.95 TWD (as of Jul 11, 2026), built from audited fundamentals. The current price is 12.00 TWD.
What is the quality score of 4108?
PhytoHealth Corporation has a Quality Score of 39/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of PhytoHealth Corporation (4108)?
PhytoHealth Corporation reported trailing-twelve-month revenue of about 139M TWD (latest available figure, as of Jul 11, 2026).
What is the net profit margin of 4108?
The net profit margin of PhytoHealth Corporation is about -42.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

The 25 strongest value stocks, free every month

Enter your email to get the free monthly Top-25 report of the most undervalued quality stocks from 35,000+ analysed. Unsubscribe anytime.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.